Antibacterial activity of tazocin (piperacillin/tazobactam) against 1296 clinical isolates from a tertiary care center.
The antibacterial activity of the recently developed ss-lactamase inhibitor tazobactam with and without piperacillin was studied in recent clinical isolates from patients at a tertiary care center. Although tazobactam by itself had little or no antibacterial activity, the combination with piperacillin was highly effective against piperacillin-resistant Staphylococcus aureus and Enterococci. It was also significantly more inhibitory than piperacillin towards almost all members of Enterobacteriaceae and Pseudomonas aeruginosa tested. The activity was compared with another commercially available combination of penicillin (amoxicillin and ss-lactamase inhibitor, clavulanic acid), and other drugs commonly used in clinical practice.